明志强;曹金明;陈天武;吴玉平;杨丽芹;高丹;

• 1:川北医学院附属医院放射科(医学影像四川省重点实验室)
• 2:自贡市第一人民医院放射科
• 3:南充市中心医院·川北医学院第二临床医学院影像科

摘要(Abstract)：

目的 探讨MRI对肝细胞癌射频消融术后不同疗效评价的可行性。材料与方法 回顾性分析川北医学院附属医院2018年1月至2021年6月期间收治的接受射频消融治疗的肝细胞癌病例52例，共60个病灶。收集患者治疗前及治疗后随访的MRI平扫、多期增强及扩散加权成像图像，评价肿瘤完全消融、肿瘤残余、局部肿瘤进展及新发肿瘤，分别计算其敏感度、特异度、阳性预测值(positive predictive value,PPV)、阴性预测值(negative predictive value,NPV)及准确率。结果 (1)完全消融，MRI检测的敏感度、特异度、PPV、NPV及准确率分别为89.5%、92.7%、85.0%、95.0%、91.7%;(2)肿瘤残余，MRI检测的敏感度、特异度、PPV、NPV及准确率分别为81.8%、91.8%、69.2%、95.7%、90.0%;(3)局部肿瘤进展，MRI检测的敏感度、特异度、PPV、NPV及准确率分别为84.6%、93.2%、78.6%、95.3%、91.2%;(4)新发肿瘤，MRI检测的敏感度、特异度、PPV、NPV及准确率分别为100.0%、94.7%、88.9%、100.0%、96.3%。结论 MRI用于肝细胞癌射频消融术后的疗效评价时，其对完全消融、肿瘤残余、局部肿瘤进展及新发肿瘤的评价效果良好，尤其是在完全消融及新发肿瘤方面，具有非常高的诊断价值。

关键词(KeyWords)： 肝细胞癌;射频消融;疗效评价;磁共振成像;扩散加权成像

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(编号：81050033)~~

作者(Authors): 明志强;曹金明;陈天武;吴玉平;杨丽芹;高丹;

参考文献(References)：

• [1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.DOI:10.3322/caac.21492.
• [2]Zhou MG,Wang HD,Zeng XY,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.DOI:10.1016/S0140-6736(19)30427-1.
• [3]National Health Commission of the People's Republic of China Medical Administration and Hospital Administration.Standardization for diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J].Chin J Dig Surg,2020,19(1):1-20.DOI:10.3760/cma.j.issn.1673-9752.2020.01.001.中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志,2020,19(1):1-20.DOI:10.3760/cma.j.issn.1673-9752.2020.01.001.
• [4]Jia Z,Zhang HT,Li N.Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria:a systematic review and meta-analysis of recent randomized controlled trials[J].J Gastroenterol Hepatol,2021,36(7):1769-1777.DOI:10.1111/jgh.15440.
• [5]Lee DH,Lee MW,Kim PN,et al.Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma:a multicenter clinical trial[J].Radiology,2021,301(1):229-236.DOI:10.1148/radiol.2021210309.
• [6]Lei JY,Yan LN,Li DJ,et al.Comparison of open liver resection and RFA for the treatment of solitary 3-5-cmhepatocellular carcinoma:a retrospective study[J].BMC Surg,2019,19(1):195.DOI:10.1186/s12893-019-0663-9.
• [7]Ren YQ,Zheng CS.Different imaging assessments for hepatocellular carcinoma after radiofrequency ablation:clinical application and recent progress[J].J Interv Radiol,2018,27(10):993-996.任衍乔,郑传胜.肝癌射频消融术后各种影像学评价应用与进展[J].介入放射学杂志,2018,27(10):993-996.
• [8]Ming ZQ,Cao JM,Chen TW.CT evaluation of radiof requency ablation for hepatocellular carcinoma[J].Med J West China,2021,33(5):764-770.DOI:10.3969/j.issn.1672-3511.2021.05.030.明志强,曹金明,陈天武.CT对肝细胞癌射频消融术后疗效的评价[J].西部医学,2021,33(5):764-770.DOI:10.3969/j.issn.1672-3511.2021.05.030.
• [9]Zheng JS,Fan WJ,Hu KW,et al.Expert consensus on standardized clinical application of image-guided thermal ablation of liver tumor[J].J Clin Hepatology,2017,33(10):1864-1869.DOI:10.3969/j.issn.1001-5256.2017.10.004.郑加生,范卫君,胡凯文,等.影像引导肝脏肿瘤热消融治疗技术临床规范化应用专家共识[J].临床肝胆病杂志,2017,33(10):1864-1869.DOI:10.3969/j.issn.1001-5256.2017.10.004.
• [10]Llovet JM,Lencioni R.m RECIST for HCC:performance and novel refinements[J].J Hepatol,2020,72(2):288-306.DOI:10.1016/j.jhep.2019.09.026.
• [11]Qu JR,Liu CC,Zhang HK,et al.Comparison of computed tomography versus magnetic resonance imaging in assessing radiofrequency ablation margins after radiofrequency ablation in patients with hepatocellular carcinomas[J].Acta Acad Med Sin,2012,34(5):480-485.DOI:10.3881/j.issn.1000-503X.2012.05.008.曲金荣,刘翠翠,张宏凯,等.CT和磁共振成像在肝细胞癌射频治疗后射频边缘评价中的作用[J].中国医学科学院学报,2012,34(5):480-485.DOI:10.3881/j.issn.1000-503X.2012.05.008.
• [12]Xiao B,Wang CY,Cao Y,et al.A comparative study of contrast-enhanced ultrasonograpgy versus contrast-enhanced CT in evaluating short-term efficacy of percutaneous radiofrequency ablation for hapatic carcinoma[J].Guangxi Med J,2015,37(7):931-934.DOI:10.11675/j.issn.0253-4304.2015.07.15.肖彬,王春瑜,曹阳,等.超声造影与增强CT评价经皮射频消融治疗肝癌术后近期疗效的对比研究[J].广西医学,2015,37(7):931-934.DOI:10.11675/j.issn.0253-4304.2015.07.15.
• [13]Zhang ZJ,Wu MC,Liu Q,et al.Imaging evaluation of efficacy of radiofrequency ablation treatment for hepatic cancer[J].Chin J Oncol,2005,27(10):616-619.DOI:10.3760/j.issn:0253-3766.2005.10.011.张智坚,吴孟超,刘崎,等.不同影像方法对射频消融治疗肝癌疗效的评价[J].中华肿瘤杂志,2005,27(10):616-619.DOI:10.3760/j.issn:0253-3766.2005.10.011.
• [14]Tao YY,Zhou Y,Wang R,et al.Progress of intravoxel incoherent motion diffusion-weighted imaging in liver diseases[J].World J Clin Cases,2020,8(15):3164-3176.DOI:10.12998/wjcc.v8.i15.3164.
• [15]Xie DY,Ren ZG,Zhou J,et al.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma:updates and insights[J].Hepatobiliary Surg Nutr,2020,9(4):452-463.DOI:10.21037/hbsn-20-480.
• [16]Ming ZQ,Hu XL,Chen TW.Therapeutic effects of radiofrequency ablation for hepatocellular carcinoma evaluated by CT and MRI:the current status[J].Int J Med Radiol,2021,44(6):692-697.DOI:10.19300/j.2021.Z18897.明志强,胡晓莉,陈天武.肝细胞癌射频消融术后疗效的CT及MRI评价研究现状[J].国际医学放射学杂志,2021,44(6):692-697.DOI:10.19300/j.2021.Z18897.
• [17]Jin S,Tan SS,Peng W,et al.Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma:a systematic review and meta-analysis[J].World J Surg Oncol,2020,18(1):199.DOI:10.1186/s12957-020-01966-w.
• [18]Wang J,Yang SJ,Li Y.The value of magnetic resonance imaging in evaluating the efficacy of radiofrequency ablation for primary liver cancer[J].Chin J Med Imaging,2020,4(15):18-20.DOI:10.3969/j.issn.2096-3807.2020.15.010.王佳,杨素君,李莹.原发性肝癌热消融术后疗效的MRI评价[J].医学影像学杂志,2020,4(15):18-20.DOI:10.3969/j.issn.2096-3807.2020.15.010.
• [19]Kobe A,Kindler Y,Klotz E,et al.Fusion of preinterventional MRimaging with liver perfusion CT after RFA of hepatocellular carcinoma:early quantitative prediction of local recurrence[J].Invest Radiol,2021,56(3):188-196.DOI:10.1097/RLI.0000000000000726.
• [20]Keller S,Chapiro J,Brangsch J,et al.Quantitative MRI for assessment of treatment outcomes in a rabbit VX2 hepatic tumor model[J].J Magn Reson Imaging,2020,52(3):668-685.DOI:10.1002/jmri.26968.
• [21]Tang J,Li JF,Liu FY,et al.The progress and advance on diffusion-weighted imaging in locoregional interventional treatment of hepatocellular carcinoma[J].Chin J Hepatobiliary Surg,2021,27(3):235-240.DOI:10.3760/cma.j.cn113884-20200511-00259.唐静,李金锋,刘凤永,等.扩散加权成像在肝癌行局部介入治疗中的应用现状及研究进展[J].中华肝胆外科杂志,2021,27(3):235-240.DOI:10.3760/cma.j.cn113884-20200511-00259.
• [22]Wang DD,Li XG.Residual tumor after radiofrequency ablation of hepatocellular carcinoma:its current situation and research progress[J].J Interv Radiol,2019,28(8):800-804.DOI:10.3969/j.issn.1008-794X.2019.08.021.王东东,李晓光.肝癌射频消融后肿瘤残余的研究现状与进展[J].介入放射学杂志,2019,28(8):800-804.DOI:10.3969/j.issn.1008-794X.2019.08.021.
• [23]Koda M,Tokunaga S,Miyoshi K,et al.Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma[J].Eur J Radiol,2012,81(10):2730-2736.DOI:10.1016/j.ejrad.2011.11.013.
• [24]Yin N,Guo Z,Fu JF,et al.Evaluation of local efficacy of ablation of liver tumor on 3.0 T MRI and CT[J].Mod Med J,2020,48(3):311-316.DOI:10.3969/j.issn.1671-7562.2020.03.005.尹娜,郭震,付金凤,等.3.0 T MRI与CT对肝脏肿瘤射频消融术后局部疗效评价的比较[J].现代医学,2020,48(3):311-316.DOI:10.3969/j.issn.1671-7562.2020.03.005.
• [25]Granata V,Grassi R,Fusco R,et al.Abbreviated MRI protocol for the assessment of ablated area in HCC patients[J].Int J Environ Res Public Health,2021,18(7):3598.DOI:10.3390/ijerph18073598.
• [26]Rimola J,Forner A,Sapena V,et al.Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma[J].Eur Radiol,2020,30(1):186-194.DOI:10.1007/s00330-019-06351-0.
• [27]Tang J,Liu FY,Yuan HJ,et al.Pretreatment apparent diffusion coefficient as a predictor of response to transcatheter arterial chemoembolization immediately combined with radiofrequency ablation for treatment of solitary large hepatocellular carcinoma[J].Cancer Manag Res,2020,12:10127-10138.DOI:10.2147/CMAR.S270470.